Medindia

X

Shire Shares Dip 11 Percent as FDA Approves Generic Rival Drug

by Kathy Jones on  June 28, 2012 at 9:43 PM Corporate News   - G J E 4
The US Food and Drug Administration's decision to approve a rival company's petition to market a cheaper version of hyperactivity drug Adderall XR has proved to be costly for British drug maker Shire as its shares slumped by more than 11 percent on Monday
 Shire Shares Dip 11 Percent as FDA Approves Generic Rival Drug
Shire Shares Dip 11 Percent as FDA Approves Generic Rival Drug
Advertisement

Shire shares plunged 11.70 percent to stand at 1,736 pence -- heading the losers board on London's benchmark FTSE 100 index, which was down 0.96 percent at 5,460.59 points in afternoon trading.

Advertisement
The stock sank after US regulators ruled against Shire, which said in a statement that they had approved generic copies of Adderall XR from Watson Pharmaceuticals' recently acquired Actavis unit.

"Shire announces that the US Food and Drug Administration has responded to its citizen petition for Adderall XR and has approved one abbreviated new drug application for generic Adderall XR," Shire said in a statement.

-- Dow Jones Newswires contributed to this story --

Source: AFP
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All